The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term safety of belzutifan in von Hippel-Lindau syndrome: A single-center experience.
 
Paulo Siqueira do Amaral
No Relationships to Disclose
 
Aaron Winer
No Relationships to Disclose
 
Morgan Lambrecht
No Relationships to Disclose
 
Elizabeth Kaiser
No Relationships to Disclose
 
Robin Tumlinson
No Relationships to Disclose
 
Patrick D. Kelly
No Relationships to Disclose
 
Robert A. Ramirez
No Relationships to Disclose
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; Fusion Pharmaceuticals; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera; RAPT Therapeutics
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera; Seagen
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera
 
Alexander Mohler
No Relationships to Disclose
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai
 
Katy Beckermann
Consulting or Advisory Role - Adicet Bio; Alpine Immune Sciences; Aravive; Arcus Biosciences; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Nimbus Therapeutics; Xencor
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Pionyr (Inst)